It's been a mediocre week for Curis, Inc. (NASDAQ:CRIS) shareholders, with the stock dropping 19% to US$2.10 in the week since its latest annual results. Results were mixed, with revenues of US$11m beating expectations by 12%. Curis continued to be lossmaking, reporting a US$6.88 statutory loss per share, in line with analyst forecasts. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following last week's earnings report, Curis' five analysts are forecasting 2025 revenues to be US$11.0m, approximately in line with the last 12 months. Losses are predicted to fall substantially, shrinking 37% to US$3.23. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$8.51m and losses of US$4.19 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.

View our latest analysis for Curis

Despite these upgrades,the analysts have not made any major changes to their price target of US$20.00, implying that their latest estimates don't have a long term impact on what they think the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Curis at US$26.00 per share, while the most bearish prices it at US$16.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's also worth noting that the years of declining revenue look to have come to an end, with the forecast stauing flat to the end of 2025. Historically, Curis' top line has shrunk approximately 1.1% annually over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 20% per year. So it's pretty clear that, although revenues are improving, Curis is still expected to grow slower than the industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Curis. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Curis going out to 2027, and you can see them free on our platform here..

We don't want to rain on the parade too much, but we did also find 5 warning signs for Curis (2 are significant!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.